Abstract library

1849 results for "Patient derived tumour xenografts".
#1107 The Chicken Chorioallantoic Membrane Assay as a Preclinical Model for the Research of Rare Gastrointenstinal Neuroendocrine Tumours
Introduction: Preclinical trials of cancer therapeutics require both in vitro and in vivo evaluations. For neuroendocrine tumours (NET) studies are limited to cell lines, thus xenograft models are needed for screening and evaluation of anti-cancer drugs. The chick chorioallantoic membrane (CAM) assay is a well-established model system to investigate tumour growth, angiogenesis and metastasis.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: PhD Nassim Ghaffari Tabrizi-Wizsy
Authors: Passegger C, Kump P, Haybäck J, Lipp R, ...
#1648 Treatment Patterns and Survival Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden – A Population-Based Register-Linkage and Medical Chart Review Study
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is a group of neoplasms derived from the endocrine system in the GI tract and pancreas.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PhD Åse Björstad
#1263 Pretherapy Identification of Patients at Risk of Receiving a High Renal Dose Undergoing Peptide Receptor Radionuclide Therapy
Introduction: 68GaDOTA TATE imaging of patients with neuroendocrine tumours has shown that tumour sequestration is a major factor leading to a sink effect that decreases activity concentration in healthy tissues, particularly the renal parenchyma.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Steven Goodman
Keywords: dosimetry, PRRT
#1183 Establishment of a New Human Pancreatic Neuroendocrine Tumour Cell Line
Introduction: The development of new therapeutic strategies for patients with pancreatic neuroendocrine tumours is impaired by the paucity of suitable pre-clinical models. Although the two available tumour cell lines BON and QGP have a neuroendocrine phenotype, the proliferation rate is too high for a well differentiated neuroendocrine tumour.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Schrader J, Benten D, Rhotert C, Fahl M, ...
#2162 Single Cell Copy Number Variation Analysis (CNV) of Circulating Tumor Cells (CTCs) in Neuroendocrine Tumor (NET) Patients
Introduction: The identification and characterization of CTCs as part of a minimally invasive “liquid biopsy” provides an opportunity to explore NET biology, identify therapeutic targets and investigate tumour heterogeneity.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Alexa Childs
Authors: Childs A, Vesely C, Rizzo F M, Ensell L, ...
#1558 Multivisceral Transplantation and Vascularised Sentinel Forearm Flap for a Metastatic Gut-Derived Neuroendocrine Tumour: Follow-up
Introduction: We previously reported the first documented case of a novel approach in a patient with extensive mesenteric metastases from a small bowel (SB) NET: this combined multivisceral transplantation (MVT) and a vascularised sentinel forearm flap (VSFF) from the same donor.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Ashley Clift
Authors: Clift A, Giele H, Vrakas G, Reddy S, ...
#54 The clinical challenge of patients with a thoracic or neck neuroendocrine tumor: a retrospective analysis from a single Irish institution
Introduction: Thoracic and neck neuroendocrine tumors (T-N-NETs) represent a rare and intriguing condition and the management of patients with a NET localized at the thorax or neck can be extremely problematic. An expert and multidisciplinary approach is generally required for the optimal management of NET patients. A systematic multidisciplinary approach to NET patients has been recently established at our institution.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Gianluca Tamagno
#1525 Retrospective Review of Single Centre’s Experience of the Side Effects Reported by Patients Receiving Everolimus and the Potential Implications Relating to Patient Monitoring and Education
Introduction: Everolimus, an mTOR inhibitor, is a recommended therapy for patients with pancreatic neuroendocrine tumours. It has recognised toxicity profile.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Philippa Davies
Authors: Davies P, ...
#1748 External Validation of Prognostic Classification Score for Predicting Overall Survival (OS) of Patients (pts) with Advanced Well Differentiated Neuroendocrine Tumour (WDNET). Neuroendocrine European Prognostic Score (NEP Score Working Group)
Introduction: Absence of relevant prognostic score (PS) in NET
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Sara Pusceddu
#1103 Risk and Protective Factors for Midgut Carcinoid Tumours: A Case-Control Study of Prospectively Evaluated Patients
Introduction: The incidence of midgut carcinoid tumours is on the rise, but few studies have investigated risk factors for their occurrence.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Doctor Maria Rinzivillo